NKG2D CAR T Cells: No Robust Efficacy Signal in Phase 1

Share this content:
Despite lack of response, results support further development
Despite lack of response, results support further development

An infusion of NKG2D-targeting chimeric antigen receptor (CAR) T cells had limited T cell expansion and persistence in patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) or relapsed/refractory multiple myeloma, a first-in-human phase 1 study found.1

NKG2D is a target that is widely expressed in solid and hematologic malignancies but either absent or poorly expressed in normal healthy cells; therefore, NKG2D-targeting CAR T-cells have the potential for broad application.

This study infused 12 patients (7 with AML) with a single dose of NKG2D-CAR T cells without lymphodepleting conditioning. No infusional toxicity, cytokine release syndrome, severe autoimmunity, CAR T cell-related encephalopathy syndrome, or death occurred. However, 120 adverse events were reported including 15% at grade 3 and 7% at grade 4. None of the grade 3 events were attributed to the T cell infusion. No dose-limiting toxicities occurred.

No objective clinical responses were seen and all patients went on to receive subsequent therapy. The median overall survival was 4.7 months with a survival rate of 75% at 3 months and 42% at 6 months. Three patients were able to achieve stable disease for longer than 1 year with subsequent therapies.

NKG2D CAR T cells were detected in 4 patients in peripheral blood, but were not detected in any patient using bone marrow. One patient with AML had transient improvements in hematologic parameters at the highest dose.

“We demonstrated safety without identifying a maximum tolerated dose at cell doses ranging 1x106 to 3x107, when administered as a single infusion without prior lymphodepleting therapy and showed feasibility of manufacturing and administration without cryopreservation,” the researchers wrote.

“We did not observe a robust efficacy signal in this initial phase 1 study. However, the NKG2D-CAR approach is still in early stages of clinical development and has several unique features and strengths.”

Editor's note: The title of this article has been updated to more accurately reflect the findings from the trial.

Reference

  1. Baumeister SH, Murad J, Werner L, et al. Phase 1 trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma [published online November 5, 2018]. Cancer Immunology Research. doi: 10.1158/2326-6066. CIR-18-0307

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs